The current financial score of Xenetic Biosciences Inc is 7.26. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 725.26K, representing a year-over-year decrease of 29.38%, while its net profit experienced a year-over-year decrease of 232.49%.
The current valuation score of Xenetic Biosciences Inc is 8.22. Its current P/E ratio is -1.40, which is -52.57% below the recent high of -0.66 and -271.23% above the recent low of -5.18.
No earnings forecast score is currently available for Xenetic Biosciences Inc. The Biotechnology & Medical Research industry's average is 8.12.
The current price momentum score of Xenetic Biosciences Inc is 4.93. Currently, the stock price is trading between the resistance level at 2.09 and the support level at 1.40, making it suitable for range-bound swing trading.
The current institutional shareholding score of Xenetic Biosciences Inc is 3.00. The latest institutional shareholding proportion is 4.97%, representing a quarter-over-quarter decrease of 53.00%.
The current risk assessment score of Xenetic Biosciences Inc is 1.85. The company's beta value is 2.20. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.